
    
      The proposed clinical trial will be a Phase I/II imaging, open label, single site study. In
      Phase I, one 18F-FAZA PET scan will be conducted in patients with known squamous cell
      carcinoma of the Head & Neck, SCLC, NSCLC, lymphoma, GGM, neuroendocrine tumours or renal
      cell carcinoma. In Phase II, three 18F-FAZA PET scans will be done on patients with the above
      tumours as follows: one pre-treatment, one mid course and one post-treatment.
    
  